New targeted drug shows promise for Hard-to-Treat lung cancer
NCT ID NCT07566052
First seen May 05, 2026 · Last updated May 07, 2026 · Updated 1 time
Summary
This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried platinum chemotherapy and immunotherapy without success. The goal is to see if setidegrasib can slow cancer growth and extend life better than the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.